Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDFibroGen, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/29/2025 | Q3 2025 | N/A | $36.71 | N/A | N/A | $1.08 M |
| 06/29/2025 | Q2 2025 | N/A | -$1.88 | N/A | N/A | $1.35 M |
| 03/30/2025 | Q1 2025 | N/A | $1.15 | N/A | N/A | $2.74 M |
| 12/30/2024 | Q4 2024 | N/A | $4.46 | N/A | N/A | $3.14 M |
| 09/29/2024 | Q3 2024 | N/A | -$4.25 | N/A | N/A | $123.00 K |
| 06/29/2024 | Q2 2024 | N/A | -$3.89 | N/A | N/A | $998.00 K |
| 03/30/2024 | Q1 2024 | N/A | -$8.32 | N/A | N/A | $25.36 M |
| 12/30/2023 | Q4 2023 | N/A | -$14.27 | N/A | N/A | $3.63 M |
| 09/29/2023 | Q3 2023 | N/A | -$16.19 | N/A | N/A | $40.13 M |
| 06/29/2023 | Q2 2023 | N/A | -$22.43 | N/A | N/A | $44.32 M |
| 03/30/2023 | Q1 2023 | N/A | -$20.25 | N/A | N/A | $36.16 M |
| 12/30/2022 | Q4 2022 | N/A | -$17.59 | N/A | N/A | $34.37 M |
| 09/29/2022 | Q3 2022 | N/A | -$24.44 | N/A | N/A | $15.74 M |
| 06/29/2022 | Q2 2022 | N/A | -$19.42 | N/A | N/A | $29.81 M |
| 03/30/2022 | Q1 2022 | N/A | -$16.98 | N/A | N/A | $60.83 M |
| 12/30/2021 | Q4 2021 | N/A | -$36.13 | N/A | N/A | $16.54 M |
| 09/29/2021 | Q3 2021 | N/A | $13.44 | N/A | N/A | $155.97 M |
| 06/29/2021 | Q2 2021 | N/A | -$36.30 | N/A | N/A | $24.36 M |
| 03/30/2021 | Q1 2021 | N/A | -$19.57 | N/A | N/A | $38.43 M |
| 12/30/2020 | Q4 2020 | N/A | -$16.08 | N/A | N/A | $65.00 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
FibroGen, Inc. Earnings: FAQ's
FibroGen, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 16th, 2026 based offlast year's report dates.
In the previous quarter, FibroGen, Inc. (:KYNB) reported $-1.61 earnings per share (EPS) to beat the analysts' consensus estimate of $-4.01 by $2.4.
The conference call for FibroGen, Inc.'s latest earnings report can be listened to online.
The conference call transcript for FibroGen, Inc.'s latest earnings report can be read online.
FibroGen, Inc. (:KYNB) has a recorded annual revenue of $29.62 M.
FibroGen, Inc. (:KYNB) has a recorded net income of $-47,579,000.FibroGen, Inc. has generated $-11.89 earnings per share over the last four quarters.
FibroGen, Inc. (:KYNB) has a price-to-earnings ratio of 0.23 and price/earnings-to-growth ratio is 0.